Home › Kidney Cancer › NCT07646847
A Study of a Side Effects and Resource Navigation Program for People With Cancer
I CARE (Immunotherapy Cutaneous Adverse Events REsearch) - A Trial With Diverse Cancer Patients to Determine the Impact of SDoH and Side Effects Navigation Program on Treatment Continuation
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Documentation of Disease o Patient must have pathologically confirmed kidney, bladder, breast, gastrointestinal or lung cancer (per EMR) * Prior Treatment o Within three weeks (+/- 3 weeks) of starting PD-1 or PD(L)-1 immune checkpoint inhibitors as monotherapy or in combination with other therapies (per EMR) * Age ≥ 18 (per EMR) * Not Pregnant and Not Nursing (per self-report) * At least one essential need (e.g., food, transportation, housing), as determined by the ICCAN Essential Needs Screener (per self-report) * Screens positive on SDOH screening tool, referred by the clinical team through traditional screening tools for SDOH assistance orand demonstrates financial need per MSK guidelines (up to 500% of the federal poverty limit) (per EMR or self-report) * Lives in New York metro area, including Long Island, New Jersey, Connecticut, and Pennsylvania (per self-report) * Can speak English or Spanish (per self-report) * Has no serious life-threatening allergies to tape or adhesives (per EMR or self-report) * Has no significant psychiatric disturbance sufficient to preclude completion of the assessment measures, interview, or informed consent (i.e., acute psychiatric symptoms which require individual treatment) (per EMR, patient's care team, or study team) * Has no presence of cognitive impairment disorder (i.e., delirium or dementia) sufficient to preclude meaningful informed consent and/or data collection (per EMR, patient's care team, or study team)
About the study
The purpose of this study is to find out if the navigation program helps participants manage immunotherapy treatment better than usual care. Investigators will also look at how the navigation program impacts participants' quality of life. Investigators will measure quality of life by having participants complete questionnaires.
What is being tested
- Immunotherapy CARE Program (other)
Sponsor: Memorial Sloan Kettering Cancer Center · Participants: 200 · Started: Jun 9, 2026
Contact the study team
- Francesca Gany, MD, MS · Phone: 646-888-8054
- Neil Shah, MBBS · Phone: 646-888-4239
Official record on ClinicalTrials.gov — NCT07646847
Locations in the U.S.
Conditions
From ClinicalTrials.gov, data retrieved Nov 15, 2026. Each study sets its own eligibility; the study team decides who can join.